匹配同胞供者造血干细胞移植与镰状细胞贫血患儿经颅多普勒血流速度的关联
该非随机对照干预研究在法国9个中心纳入67例需慢性输血的镰状细胞贫血患儿,采用倾向性评分匹配比较匹配同胞供者造血干细胞移植(32例)与标准治疗(35例)。主要终点1年时8条脑动脉最高时间平均最大血流速度在移植组为129.6 cm/s,标准治疗组为170.4 cm/s,差异-40.8 cm/s(95%CI -62.9至-18.6,P<.001)。25个分析的次要终点中4个有显著差异,包括3年最高血流速度、1年血流速度正常化率和1年及3年铁蛋白水平。作者结论认为匹配同胞供者造血干细胞移植与1年时更低的经颅多普勒血流速度显著相关,但需进一步研究评估其对临床结局的影响及更长随访。
要点
- 需因经颅多普勒血流速度持续升高而慢性输血的镰状细胞贫血患儿中,移植组1年最高血流速度129.6 cm/s vs 标准治疗组170.4 cm/s,差异-40.8 cm/s(95%CI -62.9至-18.6,P<.001)。
- 3年最高血流速度移植组112.4 cm/s vs 标准治疗组156.7 cm/s,差异-44.3(95%CI -71.9至-21.1,P=.001)。
- 1年血流速度正常化(<170 cm/s)率移植组80.0% vs 标准治疗组48.0%,差异32.0%(95%CI 0.2%至58.6%,P=.045)。
- 铁蛋白1年移植组905 ng/mL vs 标准治疗组2529 ng/mL,差异-1624(95%CI -2370至-879,P<.001);3年382 ng/mL vs 2170 ng/mL,差异-1788(95%CI -2570至-1006,P<.001)。
- 作者结论认为需进一步研究评估匹配同胞供者造血干细胞移植对临床结局的影响及更长随访。
适用人群与场景
- 年龄小于15岁、因经颅多普勒血流速度持续升高而需要慢性输血的镰状细胞贫血患儿。
- 须至少有1名同父母且无镰状细胞贫血的同胞;家庭同意进行HLA抗原分型,若找到匹配同胞供者则接受移植,若无匹配同胞供者则接受标准治疗。
- 研究在法国9个中心开展,2010年12月至2013年6月入组,3年随访至2017年1月结束。
诊断标准与关键阈值
- 入组条件:镰状细胞贫血、年龄小于15岁、因经颅多普勒血流速度持续升高需要慢性输血、至少有1名同父母且无镰状细胞贫血的同胞。
- 血流速度正常化定义为经颅多普勒血流速度<170 cm/s。
- 主要终点为1年时经颅多普勒测得的8条脑动脉中最高时间平均最大血流速度。
处置流程与药物剂量
- 匹配同胞供者造血干细胞移植组(n=32)接受匹配同胞供者造血干细胞移植。
- 标准治疗组(n=35)接受输血至少1年,此后可能转换为羟基脲。
研究设计与关键结果
- 非随机对照干预研究,法国9个中心,纳入67例镰状细胞贫血患儿(中位年龄7.6岁;35例女孩[52%];7例有卒中史),采用倾向性评分匹配比较匹配同胞供者造血干细胞移植(n=32)与标准治疗(n=35)。
- 主要终点:匹配样本中1年最高经颅多普勒血流速度移植组129.6 cm/s vs 标准治疗组170.4 cm/s,差异-40.8 cm/s(95%CI -62.9至-18.6;P<.001)。
- 25个分析的次要终点中4个有显著差异:3年最高血流速度移植组112.4 cm/s vs 标准治疗组156.7 cm/s,差异-44.3(95%CI -71.9至-21.1;P=.001);1年正常化率移植组80.0% vs 标准治疗组48.0%,差异32.0%(95%CI 0.2%至58.6%;P=.045);1年铁蛋白移植组905 ng/mL vs 标准治疗组2529 ng/mL,差异-1624(95%CI -2370至-879;P<.001);3年铁蛋白移植组382 ng/mL vs 标准治疗组2170 ng/mL,差异-1788(95%CI -2570至-1006;P<.001)。
- 作者结论:在因经颅多普勒血流速度持续升高而需要慢性输血的镰状细胞贫血患儿中,匹配同胞供者造血干细胞移植与1年时更低的经颅多普勒血流速度显著相关;需进一步研究评估匹配同胞供者造血干细胞移植对临床结局的影响及更长随访。
- 试验注册号:ClinicalTrials.gov NCT01340404。
证据类型、等级与局限
- 证据类型:非随机对照干预研究(倾向性评分匹配)。
- 局限:作者指出需进一步研究评估匹配同胞供者造血干细胞移植对临床结局的影响及更长随访。
对床旁实践的改变
- 对于因经颅多普勒血流速度持续升高而需要慢性输血的镰状细胞贫血患儿,若有匹配同胞供者,匹配同胞供者造血干细胞移植与1年时更低的经颅多普勒血流速度相关(移植组129.6 cm/s vs 标准治疗组170.4 cm/s)。
- 作者认为需进一步研究评估匹配同胞供者造血干细胞移植对临床结局的影响及更长随访。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: In children with sickle cell anemia (SCA), high transcranial Doppler (TCD) velocities are associated with stroke risk, which is reduced by chronic transfusion. Whether matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT) can reduce velocities in patients with SCA is unknown.
OBJECTIVE: To determine the association of MSD-HSCT with TCD velocities as a surrogate for the occurrence of ischemic stroke in children with SCA.
DESIGN, SETTING, AND PARTICIPANTS: Nonrandomized controlled intervention study conducted at 9 French centers. Patients with SCA were enrolled between December 2010 and June 2013, with 3-year follow-up ending in January 2017. Children with SCA were eligible if younger than 15 years, required chronic transfusions for persistently elevated TCD velocities, and had at least 1 sibling without SCA from the same 2 parents. Families agreed to HLA antigen typing and transplantation if a matched sibling donor was identified or to standard care in the absence of a matched sibling donor.
EXPOSURES: MSD-HSCT (n = 32), compared with standard care (n = 35) (transfusions for ≥1 year with potential switch to hydroxyurea thereafter), using propensity score matching.
MAIN OUTCOMES AND MEASURES: The primary outcome was the highest time-averaged mean of maximum velocities in 8 cerebral arteries, measured by TCD (TCD velocity) at 1 year. Twenty-five of 29 secondary outcomes were analyzed, including the highest TCD velocity at 3 years and normalization of velocities (<170 cm/s) and ferritin levels at 1 and 3 years.
RESULTS: Sixty-seven children with SCA (median age, 7.6 years; 35 girls [52%]) were enrolled (7 with stroke history). In the matched sample, highest TCD velocities at 1 year were significantly lower on average in the transplantation group (129.6 cm/s) vs the standard care group (170.4 cm/s; difference, -40.8 cm/s [95% CI, -62.9 to -18.6]; P < .001). Of the 25 analyzed secondary end points, 4 showed significant differences, including the highest TCD velocity at 3 years (112.4 cm/s in the transplantation group vs 156.7 cm/s in the standard care group; difference, -44.3 [95% CI, -71.9 to -21.1]; P = .001); normalization rate at 1 year (80.0% in the transplantation group vs 48.0% in the standard care group; difference, 32.0% [95% CI, 0.2% to 58.6%]; P = .045); and ferritin levels at 1 year (905 ng/mL in the transplantation group vs 2529 ng/mL in the standard care group; difference, -1624 [95% CI, -2370 to -879]; P < .001) and 3 years (382 ng/mL in the transplantation group vs 2170 ng/mL in the standard care group; difference, -1788 [95% CI, -2570 to -1006]; P < .001).
CONCLUSIONS AND RELEVANCE: Among children with SCA requiring chronic transfusion because of persistently elevated TCD velocities, MSD-HSCT was significantly associated with lower TCD velocities at 1 year compared with standard care. Further research is warranted to assess the effects of MSD-HSCT on clinical outcomes and over longer follow-up.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01340404.
参考来源
- Bernaudin F, Verlhac S, Peffault de Latour R, et al. Association of Matched Sibling Donor Hematopoietic Stem Cell Transplantation With Transcranial Doppler Velocities in Children With Sickle Cell Anemia. JAMA. 2019. PMID: 30667500. doi:10.1001/jama.2018.20059
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。